Forensic Analysis · Medical Devices · as of Nov 9, 2026
Haemonetics Corp (HAE)
A forensic read on Haemonetics Corp built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
B · Sound & dependable
Forensic grade
Safe
Financial health
2.9
Distress distance
Clean
Earnings quality
2
Forensic signals
12.0%
ROE
-2.0%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (auditor quality, say on pay, board independence, going concern). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Haemonetics Corp earns a B (Sound & dependable) forensic quality grade, and its balance-sheet distress test reads 2.9, placing it in the Safe zone. 2 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
6.4%
FY2026
Return on invested capital.Return on invested capital is 6.4% in the latest fiscal year, against 7.4% in FY2024, having run between 6.4% and 9.8% across FY2024–FY2026 with no direction held. After-tax operating profit was $128M in FY2024 and $119M in FY2026, with operating income at 12.6% of revenue in FY2024, 16.3% in FY2025 and 11.7% in FY2026. The capital base behind it went from $1.7B in FY2024 to $1.9B in FY2026 (+8%), while the revenue it carried went from $1.3B to $1.3B. Across FY2025–FY2026, $298M went into capital expenditure and acquisitions against $121M of depreciation excluding $106M of intangible-asset amortisation. The base is struck net of amortisation, write-downs and the current liabilities that fund it, so it moved by less than that spending net of the wear, and this row does not say which of those absorbed the difference. FY2026's operating profit carried a $87M asset write-down and a $3M restructuring charge that alone took about 3.6 points off that year's return, so more than the whole 1.0-point fall across FY2024–FY2026 is that charge landing in the latest year rather than the capital earning less. A non-cash write-down lowers the reported return in the year it lands.
224d
FY2025→FY2026
Inventory days.Days inventory outstanding moved from 204 to 224 FY2025→FY2026 (against cost of goods sold; inventory -16% vs -11% in cost of sales). Inventory ended the year no higher than it began, but days on hand lengthened on the year's average balance — watch for markdowns.
Key fundamentals
Latest Revenue$1.33B
Revenue Growth YoY-2.0%
Revenue CAGR (2yr)+0.9%
Net Margin7.3%
Free Cash Flow$253.7M
Return on Equity12.0%
Debt / Equity1.54x
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Haemonetics Corp's actual 10-K/10-Q/8-K filings?